As of June 22, the medically insured persons will benefit from more compensated drugs. The list of medicines whose costs are compensated with money from the mandatory health insurance funds was extended by 11 common international names, IPN reports.
The list now includes glimepiride for treating type II diabetes and brimonidinum+timololum for treating glaucoma. Both are fully compensated.
A number of medicines for treating cardiovascular diseases, such as telmisartanum, nebivololum, perindoprilum and carvedilolum, will be 70% compensated on average.
There will also be compensated two new drugs for episodic hospital treatment during the day. These are: pantoprazolum for treating gastric and duodenal ulcer, and pregabalinum for episodically treating diabetic neuropathy. For adults, these drugs will be 70% compensated, while for children they will be fully compensated.
Also, aceclofenacum for treating rheumatoid arthritis and osteoarthritis will be 50% compensated, while lercanidipinum for treating cardiovascular diseases and salmeterol xinafoate for chronic obstructive bronchopneumonia and bronchial asthma will be 30% compensated on average.
The common international names valsartanum for treating cardiovascular diseases, diclofenacum for treating rheumatoid arthritis and osteoarthritis and allopurinolum for gout, which were used for episodic hospital treatment during the day, will be now prescribed for long-term treatment.
The list of compensated medicines is available from the family doctor and drugstores and on the website of the National Health Insurance Company and can also be consulted through the Company’s information service on 0 800 99999.
